Autoimmune & Inflammatory Focused Drug Discovery and Early Pre-Clinical Development

Kyowa Kirin is a Japan-based global speciality pharmaceutical company that uses its deep expertise in antibody engineering and a passion for innovative drug discovery to target new disease pathways. They've delivered breakthrough medicines in oncology, nephrology, central nervous system and immunology. They are seeking to identify next-generation biologics and small molecule drugs within the autoimmune and inflammation therapeutic areas.

Approaches of Interest

- Early-stage drug discovery and preclinical research to identify and advance next-generation biologics and small molecule drugs within immune-related (autoimmune / inflammation) disease areas
- Antibodies, proteins, small molecule modalities which:
  1. Have a novel biological mode of action against target cells or target molecules
  2. Potentially modulate molecules that have been thought as difficult to target with conventional drugs
  3. Potentially have a competitive edge over the standard of care and existing drugs in the target indications
  4. Potentially have effects on patient segments refractory to conventional therapies
- Kyowa Kirin is also interested in novel druggable targets with a clear linkage to human disease (e.g. modulator activity), along with novel mechanisms of action. Drug repurposing opportunities are also of interest
- Indications with higher unmet needs (e.g. scleroderma, dermatomyositis), including rare skin diseases, are of highest interest

Stage of Development

Kyowa Kirin is interested in research at the basic stage through to the late preclinical stage, with opportunities with in vitro and/or in vivo validation preferred.

Out of Scope

- Cell therapy and nucleic acid medicine (RNA silencing) based approaches are of low priority
- Rheumatoid arthritis, asthma and multiple sclerosis are not of interest. Psoriasis is only of interest if it is a novel mechanism of action/pathway

Opportunity for Collaboration and Submission Information

- Kyowa Kirin is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis. Example outcomes include licensing assets, project/PhD funding, and research collaborations
- Submission of one page, 200-300 word briefs are encouraged. In submitting to this campaign, you confirm that your submission contains only non-confidential information

Opportunities sought

- Technologies
- Academics and expertise
- Centres of excellence
- Research projects
- Spinout companies

Submissions

Please submit relevant, non-confidential opportunities online via: discover.in-part.com

Deadline: 11th August 2021 - 10:59 pm GMT

Have any questions?
Contact our team at discover@in-part.co.uk

Kyowa Kirin strives to create and deliver novel medicines with life changing value. With a heritage of more than 70 years, the company applies cutting edge science including an expertise in antibody research and engineering, to address the needs of patients and society across multiple therapeutic areas.